Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Cited by (1,001)

Items 301–400 of 1,001

1. Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial
   Peter B. Gilbert, Youyi Fong, Nima S. Hejazi, Avi Kenny, Ying Huang, Marco Carone, David C. Benkeser, Dean A. Follmann · 2024 · Vaccine
2. SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals
   Rebecca Urschel, Saskia Bronder, Verena Klemis, Stefanie Marx, Franziska Hielscher, Amina Abu‐Omar, Candida Guckelmus, Sophie Schneitler, Christina Baum, Sören L. Becker et al. · 2024 · Nature Communications
3. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
   Corleis, Björn, Hoffmann, Donata, Rauch, Susanne, Fricke, Charlie, Roth, Nicole, Gergen, Janina, Kovacikova, Kristina, Schlottau, Kore, Halwe, Nico Joel, Ulrich, Lorenz et al. · 2023 · Nature Communications
4. Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions
   Lindsey N. Anderson, Charles Tapley Hoyt, Jeremy Zucker, Andrew D. McNaughton, Jeremy Teuton, Klas Karis, Natasha N. Arokium-Christian, Jackson T. Warley, Zachary R. Stromberg, Benjamin M. Gyori et al. · 2025 · Frontiers in Immunology
5. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
   Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
6. The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study
   Thomas Perkmann, Patrick Mucher, Nicole Perkmann‐Nagele, Astrid Radakovics, Manuela Repl, Thomas Köller, Klaus G. Schmetterer, Johannes W. Bigenzahn, Florentina Leitner, Galateja Jordakieva et al. · 2022 · Microbiology Spectrum
7. Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
   Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander Rupert Moschen, Thomas R. Kreil · 2022 · npj Vaccines
8. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
   Josue Antonio Garcia Estrada, Chien‐Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi‐Chun Lin, Cheng‐Pin Chen, Shu‐Hsing Cheng, Robert S. Janssen, I‐Feng Lin · 2022 · Vaccines
9. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys
   Masayuki Hashimoto, Noriyo Nagata, Tomoyuki Homma, Hiroki Maeda, Keiji Dohi, Naomi M. Seki, Ken Yoshihara, Naoko Iwata‐Yoshikawa, Nozomi Shiwa-Sudo, Yusuke Sakai et al. · 2022 · Vaccine
10. Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study
    Gaëlle Dauriat, L. Beaumont, Liêm Binh Luong Nguyen, Benjamin Renaud-Picard, Morgane Penhouet, Benjamin Coiffard, Mathilde Salpin, Xavier Demant, Christel Saint Raymond, Nicolas Carlier et al. · 2022 · European Respiratory Journal
11. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial
    Lidong Gao, Yan Li, Peng He, Zhen Chen, Huaiyu Yang, Fangjun Li, Siyuan Zhang, Danni Wang, Guangyan Wang, Shilong Yang et al. · 2023 · The Lancet Child & Adolescent Health
12. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
    Quentin Clairon, Mélanie Prague, Delphine Planas, Timothée Bruel, Laurent Hocqueloux, Thiérry Prazuck, Olivier Schwartz, Rodolphe Thiébaut, Jérémie Guedj · 2023 · PLoS Computational Biology
13. Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine
    Spyros Chalkias, Frank S. Eder, Brandon J. Essink, Shishir K. Khetan, Biliana Nestorova, Jing Feng, Xing Chen, Ying Chang, Honghong Zhou, David C. Montefiori et al. · 2022 · Research Square
14. A Robust ROS Generation and Ferroptotic Lipid Modulation Nanosystem for Mutual Reinforcement of Ferroptosis and Cancer Immunotherapy
    Chao Jiang, Wenxi Li, Jie Yan, Xinying Yu, Yuzhao Feng, Bei Li, Yuan Liu, Yunlu Dai · 2024 · Advanced Healthcare Materials
15. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
    Hideaki Kato, Kei Miyakawa, Norihisa Ohtake, Hirofumi Go, Yutaro Yamaoka, Satoshi Yajima, Tomoko Shimada, Atsushi Goto, Hideaki Nakajima, Akihide Ryo · 2021 · Journal of Infection and Chemotherapy
16. The adverse reactions to vaccines practice parameter 10 years on—what have we learned?
    John M. Kelso · 2022 · Annals of Allergy Asthma & Immunology
17. Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
    Per Johan Klasse, John P. Moore · 2022 · Journal of Virology
18. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
    Justyna Sieber, Margareta Mayer, Klara Schmidthaler, Sonja Kopanja, Jeremy Vann Camp, Amelie Popovitsch, Varsha Dwivedi, Jakub Hoz, Anja Schoof, Lukas Weseslindtner et al. · 2022 · Frontiers in Immunology
19. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study
    Woo-Joong Kim, Seong‐Ho Choi, Ji Young Park, Jung Soo Song, Jin-Won Chung, Sang Tae Choi · 2022 · Annals of the Rheumatic Diseases
20. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
    Fareed Khawaja, Genovefa A. Papanicolaou, Sanjeet Dadwal, Steven A. Pergam, John R. Wingard, Zeinab El Boghdadly, Maheen Z. Abidi, Alpana Waghmare, Zainab Shahid, Laura Michaels et al. · 2022 · Transplantation and Cellular Therapy
21. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
    Clara Bessen, Carlos Plaza‐Sirvent, Agit Simsek, Jaydeep Bhat, Corinna Sophie Marheinecke, Doris Urlaub, Petra Bonowitz, Sandra Buße, Sabrina Schumann, Elena Vidal Blanco et al. · 2022 · Frontiers in Immunology
22. SARS-CoV-2 spike conformation determines plasma neutralizing activity
    John E. Bowen, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Cameron Stewart, M. Alejandra Tortorici, Nicholas Franko, Jennifer K. Logue, Ignacio G. Mazzitelli, Sasha W. Tilles et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
23. HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
    Brittany L Ober Shepherd, David Chang, Sandhya Vasan, Julie A. Ake, Kayvon Modjarrad · 2022 · Current HIV/AIDS Reports
24. Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch
    Benjamin Hewins, Motiur Rahman, Jesús F. Bermejo-Martín, Alyson A. Kelvin, Christopher D. Richardson, Salvatore Rubino, Anuj Kumar, Pacifique Ndishimye, Ali Toloue Ostadgavahi, Abdullah Mahmud-Al-Rafat et al. · 2022 · Frontiers in Virology
25. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
    Hana M. El Sahly, Lindsey Robert Baden, Brandon J. Essink, David C. Montefiori, Adrian McDermont, Richard E. Rupp, Michael Lewis, Shobha Swaminathan, Carl Griffin, Veronica G. Fragoso et al. · 2022 · The Journal of Infectious Diseases
26. Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19
    Daniel J. Schuster, Shelly Karuna, Caroline Brackett, Martina S. Wesley, Shuying S. Li, Nathan Eisel, DeAnna Tenney, Sir’Tauria Hilliard, Nicole L. Yates, Jack Heptinstall et al. · 2022 · JCI Insight
27. The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults
    Michael Asamoah-Boaheng, David A. Goldfarb, Mohammad Ehsanul Karim, Sheila F. O’Brien, Nechelle Wall, Steven J. Drews, Vilte Barakauskas, Agatha N. Jassem, Brian E. Grunau · 2022 · The Journal of Infectious Diseases
28. The persistence of memory: defining, engineering, and measuring vaccine durability
    Amy Palin, Galit Alter, Shane Crotty, Ali H. Ellebedy, M. Chelsea Lane, Frances Eun-Hyung Lee, Michela Locci, Angela Malaspina, Conrad M. Mallia, M. Juliana McElrath et al. · 2022 · Nature Immunology
29. An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
    Alexandre Nicolas, Gérémy Sannier, Mathieu Dubé, Manon Nayrac, Alexandra Tauzin, Mark M. Painter, Rishi R. Goel, Mélanie Laporte, Gabrielle Gendron‐Lepage, Halima Medjahed et al. · 2022 · iScience
30. A controlled effects approach to assessing immune correlates of protection
    Peter B. Gilbert, Youyi Fong, Avi Kenny, Marco Carone · 2022 · Biostatistics
31. Suppressed IgG4 class switching in dupilumab‐ and TNF inhibitor‐treated patients after mRNA vaccination
    Anika M. Valk, Jim B. D. Keijser, Koos P J van Dam, Eileen W Stalman, Luuk Wieske, Maurice Steenhuis, Laura Y. L. Kummer, Phyllis Ira Spuls, Marcel W. Bekkenk, Annelie H. Musters et al. · 2024 · Allergy
32. COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response
    Ethan G. Dutcher, Elissa S. Epel, Ashley E. Mason, Frederick M. Hecht, James E. Robinson, Stacy S. Drury, Aric A. Prather · 2024 · Annals of Internal Medicine
33. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination
    Stefan Gravenstein, Frank DeVone, Oladayo Ayobami Oyebanji, Yasin Abul, Yi Cao, Philip A. Chan, Christopher W. Halladay, James L. Rudolph, Clare Nugent, Jürgen Bosch et al. · 2024 · EBioMedicine
34. Correlation Between Postvaccination Anti-Spike Antibody Titers and Protection Against Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Population-Based Longitudinal Study
    Giulia Vivaldi, David A. Jolliffe, Sian Elizabeth Faustini, Adrian Matthew Shields, Hayley Holt, Natalia Perdek, Mohammad Talaei, Florence A. S. Tydeman, Emma S. Chambers, Weigang Cai et al. · 2022 · The Journal of Infectious Diseases
35. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
    Avi Kenny, Janine van Duijn, One Dintwe, Jack Heptinstall, Randy Burnham, Sheetal S. Sawant, Lu Zhang, Dieter Mielke, Sharon Khuzwayo, Faatima Laher Omar et al. · 2024 · EBioMedicine
36. Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection
    Chang Liu, Tim K. Tsang, Sheena G. Sullivan, Benjamin John Cowling, Bingyi Yang · 2025 · Nature Communications
37. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
    Sherin Juliet Rouhani, Jovian Yu, Daniel J. Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, Athalia Rachel Pyzer, Jonathan Trujillo, Benjamin Avi Derman, Peter H. O’Donnell et al. · 2022 · Journal for ImmunoTherapy of Cancer
38. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections
    Jim B. Boonyaratanakornkit, Michael Boeckh, Alpana Waghmare · 2022 · Current Opinion in Infectious Diseases
39. Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia
    Joshua Szanyi, Tim E. Wilson, Samantha Howe, Jessie Zeng, Hassan Andrabi, Shania Rossiter, Tony A Blakely · 2023 · The Lancet Regional Health - Western Pacific
40. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
    Lisa Seekircher, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, David Bante, Lukas Forer, Sebastian Schönherr, Zoltán Bánki et al. · 2023 · The Lancet Microbe
41. COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study
    Heather Whitaker, Ruby S. M. Tsang, Rachel C. Byford, Carole Aspden, Elizabeth Button, Praveen Sebastian Pillai, Gavin Jamie, Debasish Kar, John Williams, Mary Sinnathamby et al. · 2023 · Journal of Infection
42. SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio
    Alessandra Vergori, Alessandro Tavelli, Giulia Matusali, Anna Maria Azzini, Matteo Augello, Valentina Mazzotta, Giovanni Francesco Pellicanò, Andrea Costantini, Antonio Cascio, Andrea DE VITO et al. · 2023 · Vaccines
43. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
    Grace Kenny, Sophie R O’Reilly, Neil E. Wrigley Kelly, Riya Negi, Colette Marie Gaillard, Dana Alalwan, Gurvin Saini, Tamara Alrawahneh, Nathan Francois, Matthew Angeliadis et al. · 2023 · Nature Communications
44. Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis
    Mark Manak, Luc Gagnon, Steven Phay-Tran, Philipa Levesque-Damphousse, Aymeric Fabié, Matthieu Daugan, S. Khan, Pamela C. Proud, Bethan Hussey, Daniel Knott et al. · 2024 · The Lancet Microbe
45. SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review
    Yeqing Sun, Weijin Huang, Hongyu Xiang, Jianhui Nie · 2024 · Vaccines
46. Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
    Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel J. Raskin, Hisaaki Kawabata, Levy A. Sominsky, Jordan J. Clark, Daniel C. Adelsberg, Dominika A. Bielak et al. · 2021 · medRxiv
47. Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
    Christopher J. De Voss, Marcellus, Shuailin Li, Alberta Ateere, Helen McShane, Elena Stylianou · 2025 · Frontiers in Immunology
48. SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
    Shilei Ding, Damien Adam, Guillaume Beaudoin-Bussières, Alexandra Tauzin, Shang Yu Gong, Romain Gasser, Annemarie Laumaea, Sai Priya Anand, Anik Privé, Catherine Bourassa et al. · 2021 · Viruses
49. Using correlates to accelerate vaccinology
    Peter Openshaw · 2022 · Science
50. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain
    Jiajing Wu, Jianhui Nie, Li Zhang, Hao Song, Yimeng An, Ziteng Liang, Jing Yang, Ruxia Ding, Shuo Liu, Qianqian Li et al. · 2022 · Signal Transduction and Targeted Therapy
51. Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
    Nancy Leung, Samuel M. S. Cheng, Mario Martín-Sánchez, Niki Y. M. Au, Yvonne Y Ng, Leo L. H. Luk, Kaimin Chan, John K. C. Li, Yonna W. Y. Leung, Leo C. H. Tsang et al. · 2022 · Clinical Infectious Diseases
52. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
    Alina Seidel, Michelle Zanoni, Rüdiger M. Groß, Daniela Krnavek, Sümeyye Erdemci-Evin, Pascal von Maltitz, Dan Albers, Carina Conzelmann, Sichen Liu, Tatjana Weil et al. · 2022 · Frontiers in Immunology
53. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
    Daniel Mrak, Felix Kartnig, Daniela Sieghart, Elisabeth Simader, Helga Radner, Péter Mandl, Lisa Göschl, Philipp Hofer, Thomas Deimel, Irina Gessl et al. · 2022 · Journal of Autoimmunity
54. Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China
    Sanyi Tang, Xia Wang, Biao Tang, Sha He, Dingding Yan, Chenxi Huang, Yiming Shao, Yanni Xiao, Robert Cheke · 2023 · BMC Public Health
55. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021
    Tom Woudenberg, Laurie Pinaud, Laura García, Laura Tondeur, Stéphane Pelleau, Alix De Thoisy, Françoise Donnadieu, Marija Backović, Mikaël Attia, Nathanaël Hozé et al. · 2023 · Eurosurveillance
56. Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation
    Alison Generotti, Ryne Contreras, Brenden Zounes, Eric Schade, Andrea Kemme, Yatish S. Rane, Xinggang Liu, Dustin Elwood, Katherine Schultheis, Jeremy O. Marston et al. · 2023 · Molecular Therapy — Nucleic Acids
57. Testing for SARS-CoV-2: lessons learned and current use cases
    Elitza S. Theel, James E. Kirby, Nira R. Pollock · 2024 · Clinical Microbiology Reviews
58. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
    Angelos E. Hatzakis, Andreas Karabinis, Sotirios Roussos, Nikos Pantazis, Dimitrios Degiannis, Antigoni S. Chaidaroglou, Konstantinos Th. Petsios, Ioanna D. Pavlopoulou, Sotirios Tsiodras, Dimitrios N. Paraskevis et al. · 2022 · Vaccines
59. Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
    Takafumi Tsushima, Toshiki Terao, Kentaro Narita, Ami Fukumoto, Daisuke Ikeda, Yuya Kamura, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi et al. · 2022 · International Journal of Hematology
60. Temporal Associations of B and T Cell Immunity with Robust Vaccine Responsiveness in a 16-Week Interval BNT162B2 Regimen
    Manon Nayrac, Mathieu Dubé, Gérémy Sannier, Alexandre Nicolas, Lorie Marchitto, Olivier Tastet, Alexandra Tauzin, Nathalie Brassard, Raphaël Lima-Barbosa, Guillaume Beaudoin-Bussières et al. · 2022 · Cell Reports
61. Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
    Thayne H. Dickey, Rui Ma, Sachy Orr-Gonzalez, Tarik Ouahes, Palak Y. Patel, Holly McAleese, Brandi Butler, Elizabeth Eudy, Brett Eaton, Michael J. Murphy et al. · 2023 · Cell Reports
62. Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection
    George Ronald Nahass, Rachel E.A. Salomon, Grace Blacker, Kazim Haider, Rich Brotherton, Kristine Teague, Ying Ying Yiu, Rachel E. Brewer, Sarah Galloway, Paige S. Hansen et al. · 2021 · medRxiv
63. Deaths averted by vaccination due to reduced transmission can exceed those from direct protection of vaccinated individuals for SARS-CoV-2
    Billy J. Gardner, Auston Marm Kilpatrick · 2021 · medRxiv
64. An immune correlate of SARS-CoV-2 infection and severity of reinfections
    Hannah E. Maier, Ángel Balmaseda, Sergio Ojeda, Cristhiam Cerpas, Nery Sánchez, Miguel Plazaola, Harm van Bakel, John Kubale, Roger López, SAIRA INDIRA SABORÍO et al. · 2021 · medRxiv
65. mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
    Girard, Bethany, Tomassini, Joanne E, Deng, Weiping, Maglinao, Maha, Zhou, Honghong, Figueroa, Amparo, Ghamloush, Sabine Schnyder, Montefiori, David C, Das, Rituparna, Pajon, Rolando · 2022
66. Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation
    Sebastian Einhauser, David Peterhoff, Hans Helmut Niller, Stephanie Beileke, Felix Günther, Philipp A. Steininger, Ralph Burkhardt, Iris M. Heid, Annette B. Pfahlberg, Klaus Überla et al. · 2021 · Diagnostics
67. Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients With Chronic Pulmonary Diseases
    Zitta Barrella Harboe, Sebastian Rask Hamm, Laura Pérez‐Alós, Pradeesh Sivapalan, Helene Priemé, Torgny Wilcke, Peter Kjeldgaard, Saher Burhan Shaker, Alexander Svorre Jordan, Dina Leth Møller et al. · 2022 · BMJ Open Respiratory Research
68. Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study
    David Simón, Koray Taşçılar, Filippo Fagni, Arnd Kleyer, Gerhard Krönke, Christine Haie Meder, Peter Dietrich, Till Orlemann, Johanna Mößner, Jule Taubmann et al. · 2022 · The Lancet Rheumatology
69. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
    Michele Bartoletti, Özlem Kurt Azap, Aleksandra M. Barac, Linda Bussini, Önder Ergönül, Robert G. E. Krause, Alejandro Martín‐Quirós, José Ramón Paño‐Pardo, Nicholas Power, Marcella Sibani et al. · 2022 · Clinical Microbiology and Infection
70. Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
    Silvia Garcia-Cirera, Joan Calvet, Antonio Berenguer, Edwards Pradenas, Sílvia Marfil, Marta Massanella, Lourdes Mateu, Benjamin Trinité, María Llop-Vilaltella, Marta Arévalo et al. · 2022 · Scientific Reports
71. Emergence of SARS‐CoV‐2 Omicron variant and strategies for tackling the infection
    Yan Wu, Yiyin Long, Feng Wang, Wei Yong Liu, Yuliang Wang · 2022 · Immunity Inflammation and Disease
72. Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
    Rituparna Das, Randall N. Hyer, Paul Robert Burton, Jacqueline M. Miller, Barbara J. Kuter · 2023 · Human Vaccines & Immunotherapeutics
73. A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
    Megan A. O’Connor, David W. Hawman, Kimberly D. Meade-White, Shanna S. Leventhal, Wenjun Song, Samantha Randall, Jacob F. Archer, Thomas B. Lewis, Brieann Brown, Megan Fredericks et al. · 2023 · PLoS Pathogens
74. Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens
    Wei Wang, Emilie Goguet, Stephanie Paz, Russell A. Vassell, Simon D. Pollett, Edward E.S. Mitre, Carol D. Weiss · 2023 · The Journal of Infectious Diseases
75. Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
    Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo et al. · 2023 · Nature Communications
76. Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
    Eveline Santos da Silva, Jean-Yves Servais, Michel Kohnen, Vic Arendt, Thérèse Staub, Rejko Krüger, Guy Fagherazzi, Paul Wilmes, Judith M. Hübschen, Markus W. Ollert et al. · 2023 · International Journal of Molecular Sciences
77. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023
    Juan Manuel Carreño, Abram Luther Wagner, Brian Monahan, Gagandeep Singh, Daniel L. Floda, Ana Silvia Gonzalez-Reiche, Johnstone Tcheou, Ariel J. Raskin, Dominika A. Bielak, Sara Morris et al. · 2024 · Nature Communications
78. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
    Juanjie Tang, Youri Lee, Supriya Ravichandran, Gabrielle Grubbs, Chang Huang, Charles B. Stauft, Tony Wang, Basil Golding, Hana Golding, Surender Khurana · 2022 · Annals of the Rheumatic Diseases
79. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein
    Yuting Hong, Huilin Guo, Min Wei, Yali Zhang, Mujin Fang, Tong Cheng, Zhiyong Li, Shengxiang Ge, Xiangyang Yao, Quan Yuan et al. · 2022 · Journal of Virological Methods
80. Evaluation of the effect of Loigolactobacillus coryniformis K8 CECT 5711 consumption in health care workers exposed to COVID-19
    Raquel Rodríguez-Blanque, Juan Carlos Sánchez-García, Ángel Cobos Vargas, Ana Aguilar Quesada, Jose A. Maldonado-Lobón, Mónica M. Olivares, Ruth Blanco-Rojo · 2022 · Frontiers in Nutrition
81. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
    Ilana Katz Sand, Sacha Gnjatic, Florian Krammer, Kevin Tuballes, Juan Manuel Carreño, Sammita Satyanarayan, Susan Filomena, Erin Staker, Johnstone Tcheou, Aaron Miller et al. · 2022 · Multiple Sclerosis and Related Disorders
82. Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission
    Madeleine F. Jennewein, Michael D. Schultz, Samuel Beaver, Peter Battisti, Julie Bakken, Derek J. Hanson, Jobaida Akther, Fen Zhou, Raodoh Mohamath, Jasneet Singh et al. · 2025 · Molecular Therapy
83. Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
    Ai-ris Yonekura Collier, Jingyou Yu, Katherine McMahan, Jinyan Liu, Caroline G. Atyeo, Jessica L. Ansel, Zachary P. Fricker, Martha Pavlakis, Michael P. Curry, Catherine Jacob-Dolan et al. · 2021 · The Journal of Infectious Diseases
84. Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy
    Lue Ping Zhao, Terry P. Lybrand, Peter B. Gilbert, Thomas R. Hawn, Joshua Tisdell Schiffer, Leonidas Stamatatos, Thomas H. Payne, Lindsay N. Carpp, Daniel E. Geraghty, Keith R. Jerome · 2021 · Viruses
85. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
    Bin Ni, Ahmad Yanis, Kevin Dee, James D. Chappell, Daniel E. Dulek, Adetola A. Kassim, Carrie Lynn Kitko, Lora D. Thomas, Natasha Halasa · 2022 · Blood Reviews
86. The Fourth Dose of CoronaVac Vaccine Results in a Small Increase of Seroconversion and Antibody Values Among Kidney Transplant Recipients
    Marina Pontello Cristelli, Mônica Rika Nakamura, Laila Almeida Viana, Helio Tedesco Silva Junior, Jose Osmar Medina-Pestana · 2022 · Transplantation
87. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
    Shô Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Seiya Ozono, Takuya Hemmi et al. · 2023 · iScience
88. Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
    Elisabeth Lea Vikse, Even Fossum, Magnhild Sekse Erdal, Olav Hungnes, Karoline Bragstad · 2023 · Influenza and Other Respiratory Viruses
89. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial
    Christian Taucher, Rajeka Lazarus, Hanna Dellago, Gabriele Maurer, Petronela Weisova, Irena Corbic Ramljak, Katrin L. Dubischar, Anders Lilja, Susanne Eder-Lingelbach, Romana Hochreiter et al. · 2023 · Journal of Infection
90. MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
    Leonie Mayer, Leonie Marie Weskamm, Anahita Fathi, Maya Kono, Jasmin Heidepriem, Verena Krähling, Sibylle C. Mellinghoff, My Linh Ly, Monika Friedrich, Svenja Hardtke et al. · 2024 · npj Vaccines
91. Vaccination of COVID ‐19 convalescent plasma donors increases binding and neutralizing antibodies against SARS‐CoV ‐2 variants
    Clara Di Germanio, Graham Simmons, Chloe Thorbrogger, Rachel Martinelli, Mars Stone, Thomas J. Gniadek, Michael Paul Busch · 2022 · Transfusion
92. Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
    Qian Wang, Ziyang Song, Jinghuan Yang, Qian He, Qunying Mao, Yu Bai, Jianyang Liu, Chaoqiang An, Xujia Yan, Bopei Cui et al. · 2022 · Emerging Microbes & Infections
93. Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
    Douglas F. Lake, Alexa J. Roeder, María J. González‐Moa, Megan A. Koehler, Erin J. Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee A. Edwards et al. · 2022 · Communications Medicine
94. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
    Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung The Tran, Siri Mjaaland, Grete Birkeland Kro, Tore Kristian Kvien, David John Warren, Jørgen Jahnsen et al. · 2022 · BMC Medicine
95. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
    Anthony T. Reder, Olaf Stüve, Stephanie K. Tankou, Thomas P. Leist · 2022 · Multiple Sclerosis Journal
96. Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
    David J. Sullivan, Massimo Franchini, Michael J. Joyner, Arturo Casadevall, Daniele Focosi · 2021 · medRxiv
97. Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
    Gatechompol, Sivaporn, Kittanamongkolchai, Wonngarm, Ketloy, Chutitorn, Prompetchara, Eakchai, Thitithanyanont, Arunee, Jongkaewwattana, Anan, Buranapraditkun, Supranee, Alameh, Mohamad-Gabriel, Ubolyam, Sasiwimol, Sophonphan, Jiratchaya et al. · 2022 · Nature Microbiology
98. SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls
    Benedikt Simon, Harald Rubey, Martin Gromann, Astrid Knopf-Völkerer, Boris Hemedi, Sonja Zehetmayer, Bernhard M. Kirsch · 2022 · Vaccines
99. CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021–July 2021
    Megha Mehrotra, Esther Lim, Katherine Lamba, Amanda Kamali, Kristina Lai, Erika Meza, Irvin Szeto, Peter V. Robinson, Cheng‐ting Tsai, David Gebhart et al. · 2022 · Open Forum Infectious Diseases
100. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
     Muneerah M Aleissa, Jessica S Little, Sonya Davey, Anna Saucier, Guohai Zhou, Isabel H Gonzalez-Bocco, Jennifer Leigh Crombie, Andrew Looka, Lindsey Robert Baden, Nicolas C. Issa et al. · 2023 · Transplantation and Cellular Therapy